These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 32675438

  • 1. Olaparib, a new hope for ovarian cancer.
    Samoon Z, Jabbar AA.
    Indian J Cancer; 2020; 57(3):346-347. PubMed ID: 32675438
    [No Abstract] [Full Text] [Related]

  • 2. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.
    Oncotarget; 2017 Jul 18; 8(29):47154-47160. PubMed ID: 28454085
    [Abstract] [Full Text] [Related]

  • 3. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF, Matulonis UA.
    Curr Oncol Rep; 2016 May 18; 18(5):29. PubMed ID: 26984416
    [Abstract] [Full Text] [Related]

  • 4. Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.
    Saleh N, Copur MS.
    Oncology (Williston Park); 2019 Jul 15; 33(7):. PubMed ID: 31365755
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.
    DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN.
    J Clin Oncol; 2020 Oct 20; 38(30):3528-3537. PubMed ID: 32749942
    [Abstract] [Full Text] [Related]

  • 7. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb 29; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract] [Full Text] [Related]

  • 8. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.
    Clin Cancer Res; 2017 Aug 01; 23(15):4086-4094. PubMed ID: 28223274
    [Abstract] [Full Text] [Related]

  • 9. Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
    Miller RE, Crusz SM, Ledermann JA.
    Future Oncol; 2019 Jun 01; 15(16):1845-1853. PubMed ID: 31037967
    [Abstract] [Full Text] [Related]

  • 10. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
    Poveda AM, Davidson R, Blakeley C, Milner A.
    Future Oncol; 2019 Nov 01; 15(32):3651-3663. PubMed ID: 31553234
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer.
    Cheng LJ, Wong G, Chay WY, Ngeow J, Tan Y, Soon SS, Aziz MIA, Pearce F, Ng K.
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun 01; 21(3):441-448. PubMed ID: 33593205
    [Abstract] [Full Text] [Related]

  • 12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M.
    Lancet Oncol; 2015 Jan 01; 16(1):87-97. PubMed ID: 25481791
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA, Barnett JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ.
    Int J Gynecol Cancer; 2013 Jun 01; 23(5):846-52. PubMed ID: 23666017
    [Abstract] [Full Text] [Related]

  • 14. PARP inhibitors plough on.
    Mullard A.
    Nat Rev Drug Discov; 2017 Mar 30; 16(4):229. PubMed ID: 28356598
    [No Abstract] [Full Text] [Related]

  • 15. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
    Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL.
    Ann Oncol; 2016 Jun 30; 27(6):1013-1019. PubMed ID: 26961146
    [Abstract] [Full Text] [Related]

  • 16. Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
    Wu L, Zhu J, Yin R, Wu X, Lou G, Wang J, Gao Y, Kong B, Lu X, Zhou Q, Wang Y, Chen Y, Lu W, Li W, Cheng Y, Liu J, Ma X, Zhang J.
    Gynecol Oncol; 2021 Jan 30; 160(1):175-181. PubMed ID: 33250205
    [Abstract] [Full Text] [Related]

  • 17. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
    Stewart J, George A, Banerjee S.
    Expert Rev Anticancer Ther; 2018 Oct 30; 18(10):947-958. PubMed ID: 30092674
    [Abstract] [Full Text] [Related]

  • 18. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    Kurnit KC, Coleman RL, Westin SN.
    Curr Treat Options Oncol; 2018 Nov 15; 19(12):1. PubMed ID: 30535808
    [Abstract] [Full Text] [Related]

  • 19. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P.
    Eur J Cancer; 2021 Nov 15; 157():415-423. PubMed ID: 34597975
    [Abstract] [Full Text] [Related]

  • 20. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    Onstad M, Coleman RL, Westin SN.
    Drugs; 2020 Oct 15; 80(15):1525-1535. PubMed ID: 32852746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.